Lupin’s Unit-2 manufacturingfacility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (USFDA). The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.